HCPCS Level II › C
HCPCS Level II codes starting with C
622 codes, page 5 of 7. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| C9147 | Injection, tremelimumab-actl, 1 mg through FY2026 | Terminated |
| C9148 | Injection, teclistamab-cqyv, 0.5 mg through FY2026 | Terminated |
| C9149 | Injection, teplizumab-mzwv, 5 mcg through FY2026 | Terminated |
| C9150 | Xenon xe-129 hyperpolarized gas, diagnostic, per study dose through FY2026 | Terminated |
| C9151 | Injection, pegcetacoplan, 1 mg through FY2026 | Terminated |
| C9152 | Injection, aripiprazole, (abilify asimtufii), 1 mg through FY2026 | Terminated |
| C9153 | Injection, amisulpride, 1 mg through FY2026 | Terminated |
| C9154 | Injection, buprenorphine extended-release (brixadi), 1 mg through FY2026 | Terminated |
| C9155 | Injection, epcoritamab-bysp, 0.16 mg through FY2026 | Terminated |
| C9156 | Flotufolastat f 18, diagnostic, 1 millicurie through FY2026 | Terminated |
| C9157 | Injection, tofersen, 1 mg through FY2026 | Terminated |
| C9158 | Injection, risperidone, (uzedy), 1 mg through FY2026 | Terminated |
| C9159 | Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity through FY2026 | Terminated |
| C9160 | Injection, daxibotulinumtoxina-lanm, 1 unit through FY2026 | Terminated |
| C9161 | Injection, aflibercept hd, 1 mg through FY2026 | Terminated |
| C9162 | Injection, avacincaptad pegol, 0.1 mg through FY2026 | Terminated |
| C9163 | Injection, talquetamab-tgvs, 0.25 mg through FY2026 | Terminated |
| C9164 | Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) through FY2026 | Terminated |
| C9165 | Injection, elranatamab-bcmm, 1 mg through FY2026 | Terminated |
| C9166 | Injection, secukinumab, intravenous, 1 mg through FY2026 | Terminated |
| C9167 | Injection, adamts13, recombinant-krhn, 10 iu through FY2026 | Terminated |
| C9168 | Injection, mirikizumab-mrkz, 1 mg through FY2026 | Terminated |
| C9169 | Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram through FY2026 | Terminated |
| C9170 | Injection, tarlatamab-dlle, 1 mg through FY2026 | Terminated |
| C9171 | Injection, pegulicianine, 1 mg through FY2026 | Terminated |
| C9172 | Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose through FY2026 | Terminated |
| C9173 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram through FY2026 | Terminated |
| C9174 | Injection, datopotamab deruxtecan-dlnk, 1 mg through FY2026 | Terminated |
| C9175 | Injection, treosulfan, 50 mg through FY2026 | Terminated |
| C9176 | Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose | Valid |
| C9248 | Injection, clevidipine butyrate, 1 mg through FY2026 | Terminated |
| C9250 | Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml | Valid |
| C9254 | Injection, lacosamide, 1 mg | Valid |
| C9257 | Injection, bevacizumab, 0.25 mg | Valid |
| C9275 | Injection, hexaminolevulinate hydrochloride, 100 mg, per study dose through FY2026 | Terminated |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | Valid |
| C9290 | Injection, bupivacaine liposome, 1 mg through FY2026 | Terminated |
| C9293 | Injection, glucarpidase, 10 units | Valid |
| C9300 | Injection, indigotindisulfonate sodium, 1 mg through FY2026 | Terminated |
| C9301 | Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose through FY2026 | Terminated |
| C9302 | Injection, zanidatamab-hrii, 2 mg through FY2026 | Terminated |
| C9303 | Injection, zolbetuximab-clzb, 1 mg through FY2026 | Terminated |
| C9304 | Injection, marstacimab-hncq, 0.5 mg through FY2026 | Terminated |
| C9305 | Injection, nipocalimab-aahu, 3 mg through FY2026 | Terminated |
| C9306 | Injection, telisotuzumab vedotin-tllv, 1 mg through FY2026 | Terminated |
| C9307 | Injection, linvoseltamab-gcpt, 1 mg through FY2026 | Terminated |
| C9308 | Injection, carboplatin (avyxa), 1 mg through FY2026 | Terminated |
| C9309 | Injection, onasemnogene abeparvovec-brve, per treatment through FY2026 | Terminated |
| C9310 | Injection, leucovorin calcium (avyxa), 1 mg through FY2026 | Terminated |
| C9311 | Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Valid |
| C9312 | Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg | Valid |
| C9313 | Injection, pivekimab sunirine-pvzy, 0.01 mg | Valid |
| C9349 | Puraply, and puraply antimicrobial, any type, per square centimeter through FY2026 | Terminated |
| C9352 | Microporous collagen implantable tube (neuragen nerve guide), per centimeter length | Valid |
| C9353 | Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length | Valid |
| C9354 | Acellular pericardial tissue matrix of non-human origin (veritas), per square centimeter | Valid |
| C9355 | Collagen nerve cuff (neuromatrix), per 0.5 centimeter length | Valid |
| C9356 | Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (tenoglide tendon protector sheet), per square centimeter | Valid |
| C9358 | Dermal substitute, native, non-denatured collagen, fetal bovine origin (surgimend collagen matrix), per 0.5 square centimeters | Valid |
| C9359 | Porous purified collagen matrix bone void filler (integra mozaik osteoconductive scaffold putty, integra os osteoconductive scaffold putty), per 0.5 cc | Valid |
| C9360 | Dermal substitute, native, non-denatured collagen, neonatal bovine origin (surgimend collagen matrix), per 0.5 square centimeters | Valid |
| C9361 | Collagen matrix nerve wrap (neuromend collagen nerve wrap), per 0.5 centimeter length | Valid |
| C9362 | Porous purified collagen matrix bone void filler (integra mozaik osteoconductive scaffold strip), per 0.5 cc | Valid |
| C9363 | Skin substitute, integra meshed bilayer wound matrix, per square centimeter | Valid |
| C9364 | Porcine implant, permacol, per square centimeter | Valid |
| C9399 | Unclassified drugs or biologicals | Valid |
| C9407 | Iodine i-131 iobenguane, diagnostic, 1 millicurie through FY2026 | Terminated |
| C9408 | Iodine i-131 iobenguane, therapeutic, 1 millicurie through FY2026 | Terminated |
| C9441 | Injection, ferric carboxymaltose, 1 mg through FY2026 | Terminated |
| C9442 | Injection, belinostat, 10 mg through FY2026 | Terminated |
| C9443 | Injection, dalbavancin, 10 mg through FY2026 | Terminated |
| C9444 | Injection, oritavancin, 10 mg through FY2026 | Terminated |
| C9445 | Injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units through FY2026 | Terminated |
| C9446 | Injection, tedizolid phosphate, 1 mg through FY2026 | Terminated |
| C9447 | Injection, phenylephrine and ketorolac, 4 ml vial through FY2026 | Terminated |
| C9448 | Netupitant 300 mg and palonosetron 0.5 mg, oral through FY2026 | Terminated |
| C9449 | Injection, blinatumomab, 1 mcg through FY2026 | Terminated |
| C9450 | Injection, fluocinolone acetonide intravitreal implant, 0.01 mg through FY2026 | Terminated |
| C9451 | Injection, peramivir, 1 mg through FY2026 | Terminated |
| C9452 | Injection, ceftolozane 50 mg and tazobactam 25 mg through FY2026 | Terminated |
| C9453 | Injection, nivolumab, 1 mg through FY2026 | Terminated |
| C9454 | Injection, pasireotide long acting, 1 mg through FY2026 | Terminated |
| C9455 | Injection, siltuximab, 10 mg through FY2026 | Terminated |
| C9456 | Injection, isavuconazonium sulfate, 1 mg through FY2026 | Terminated |
| C9457 | Injection, sulfur hexafluoride lipid microsphere, per ml through FY2026 | Terminated |
| C9458 | Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries through FY2026 | Terminated |
| C9459 | Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries through FY2026 | Terminated |
| C9460 | Injection, cangrelor, 1 mg | Valid |
| C9461 | Choline c 11, diagnostic, per study dose through FY2026 | Terminated |
| C9462 | Injection, delafloxacin, 1 mg through FY2026 | Terminated |
| C9463 | Injection, aprepitant, 1 mg through FY2026 | Terminated |
| C9464 | Injection, rolapitant, 0.5 mg through FY2026 | Terminated |
| C9465 | Hyaluronan or derivative, durolane, for intra-articular injection, per dose through FY2026 | Terminated |
| C9466 | Injection, benralizumab, 1 mg through FY2026 | Terminated |
| C9467 | Injection, rituximab and hyaluronidase, 10 mg through FY2026 | Terminated |
| C9468 | Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u. through FY2026 | Terminated |
| C9469 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg through FY2026 | Terminated |
| C9470 | Injection, aripiprazole lauroxil, 1 mg through FY2026 | Terminated |
| C9471 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg through FY2026 | Terminated |
| C9472 | Injection, talimogene laherparepvec, 1 million plaque forming units (pfu) through FY2026 | Terminated |